BrioVAD: China's heart pump enters US clinical trials amid biotech decoupling
Synopsis
A Chinese-developed heart pump called BrioVAD — the first active implantable device from China to win FDA clinical trial clearance — has been fitted to over 100 US patients with advanced heart failure, directly challenging Abbott's HeartMate 3 monopoly even as Washington and Beijing accelerate biotech decoupling.
Key Takeaways
BrioVAD , a fully magnetically levitated LVAD developed by CH Biomedical , has been implanted in more than 100 patients across the United States in an ongoing clinical trial.
In 2024 , BrioVAD became the first active implantable medical device from China to receive FDA approval for clinical trials in the US .
The trial is designed to prove non-inferiority to Abbott 's HeartMate 3 , currently the only commercially available LVAD in the United States .
Participating trial sites include Emory University in Atlanta and AdventHealth in Los Angeles , with foundational research rooted in Fuwai Hospital , China .
The trial findings, published in the Journal of Heart and Lung Transplantation last August , outlined the safety and efficacy evaluation framework for the device.
CH Biomedical's BrioVAD, a fully magnetically levitated left ventricular assist device (LVAD) developed in China, has been implanted in more than 100 patients with advanced heart failure across the United States as part of an ongoing nationwide clinical trial — making it a rare case of Chinese medical hardware advancing inside the American healthcare system despite accelerating biotech decoupling between the two countries.
What the BrioVAD does
The BrioVAD is a compact cardiac pump, slightly larger than a table tennis ball, designed to take over circulatory function when a failing left ventricle can no longer deliver oxygen-rich blood to the body. The device uses full magnetic levitation — a technology that eliminates mechanical contact between moving parts — to reduce friction, heat, and the risk of blood clotting that has historically plagued earlier-generation LVADs.
In 2024, the BrioVAD became the first active implantable medical device originating from China to receive Food and Drug Administration (FDA) clearance for clinical trials in the United States, according to the company.
The competitive backdrop
The trial is explicitly benchmarked against the market leader. According to a paper published in the Journal of Heart and Lung Transplantation last August, the trial team said the study was “designed to evaluate the safety and efficacy of the BrioVAD by demonstrating non-inferiority to HeartMate 3.” The HeartMate 3, manufactured by Abbott, is currently the only commercially available LVAD in the United States.
If BrioVAD clears the non-inferiority bar, it would represent the first credible commercial challenge to Abbott’s monopoly in the US LVAD market — a segment that carries significant reimbursement weight given Medicare coverage for qualifying heart failure patients.
Who is running the trial
The clinical programme spans multiple sites across the United States, with institutions including Emory University in Atlanta and AdventHealth in Los Angeles listed among participating centres on ClinicalTrials.gov. The device’s foundational research traces back to Fuwai Hospital in China, one of the country’s premier cardiovascular institutions, underscoring the depth of clinical expertise behind the programme.
Why it matters
The BrioVAD trial is unfolding against a backdrop of intensifying legislative and regulatory pressure to limit Chinese medical and biotech products in the US market. The fact that the device received FDA approval for trials before the current wave of decoupling measures took hold illustrates how long regulatory pipelines can outlast political cycles.
Advanced heart failure affects hundreds of thousands of patients in the United States, and LVADs serve as both a bridge to transplant and a long-term destination therapy for those ineligible for a donor heart. A second commercially viable device in this space could meaningfully expand patient access and exert downward pressure on costs.
What’s next
The trial’s non-inferiority design means results will be closely scrutinised by the FDA, cardiologists, and Abbott alike. Whether the political climate around US-China biotech trade will affect the pathway to full commercial approval — even if clinical data supports it — remains the central uncertainty to watch.
Point of View
While geopolitical sentiment shifts in months, meaning devices approved before the current political inflection point can still advance through the system. What mainstream coverage underplays is the market consequence — Abbott has held an effective monopoly on US LVAD commerce, and a credible non-inferiority challenger backed by Medicare-eligible patient populations could compress pricing in a high-value segment. The deeper tension is whether FDA commercial approval — a separate and far more politically exposed gate than trial clearance — will be insulated from the legislative mood around Chinese medical technology. Investors and hospital procurement teams should treat the trial’s interim data, not just its final read-out, as the first signal of whether this pathway remains viable.
NationPress
1 Jul 2026
Frequently Asked Questions
What is the BrioVAD and who makes it?
The BrioVAD is a fully magnetically levitated left ventricular assist device ( LVAD ) developed by CH Biomedical , a Chinese biomedical company with research roots at Fuwai Hospital in China . It is designed to pump oxygen-rich blood through the body when the heart’s left ventricle is too weak to do so on its own.
Why is the BrioVAD significant for US patients?
The BrioVAD is the first active implantable medical device from China to receive FDA clearance for clinical trials in the United States , achieved in 2024 . For patients with advanced heart failure, it represents a potential second commercially viable LVAD option alongside Abbott 's HeartMate 3 , which currently holds a monopoly in the US market.
How does BrioVAD compare to the HeartMate 3?
The trial is specifically structured to demonstrate that BrioVAD is non-inferior to the HeartMate 3 made by Abbott . According to a paper in the Journal of Heart and Lung Transplantation published last August , the study is “designed to evaluate the safety and efficacy of the BrioVAD by demonstrating non-inferiority to HeartMate 3 .”
Does US-China biotech decoupling affect the BrioVAD trial?
The BrioVAD received its FDA clinical trial clearance in 2024 , before the most recent wave of biotech decoupling measures intensified, allowing the trial to proceed. However, any future pathway to full commercial approval in the US could face greater regulatory and political scrutiny given rising US - China tensions in the medical technology sector.
Where is the BrioVAD trial taking place?
The nationwide trial spans multiple centres listed on ClinicalTrials.gov , including Emory University in Atlanta and AdventHealth in Los Angeles . More than 100 patients with advanced heart failure across the United States have received the device as part of the ongoing study.
